# IMmotion 010 (NCT03024996)

> A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03024996
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: Renal Cell Carcinoma
- Interventions: Atezolizumab; Placebo
- Enrollment: 778
- Primary outcome: Investigator-assessed Disease-Free Survival (DFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 52
- YouTube: 31
- Podcasts: 23

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=immotion-010-nct03024996

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03024996", "email": "<work email>"}; the inbox owner confirms by the emailed link.